Ex vivo gene therapy with adenovirus-mediated transforming growth factor β1 expression for endovascular treatment of aneurysm: Results in a canine bilateral aneurysm model

Journal of Vascular Surgery

Volumn 38, Issue 3, 2003, Pages 576-583

  Ribourtout, Edith ^a   Desfaits, Anne Cécile ^a   Salazkin, Igor ^a   Raymond, Jean ^a,b  

^a Notre Dame Hospital ^*

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOCRINE EFFECT; CAROTID ARTERIOGRAPHY; CAROTID ARTERY ANEURYSM; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOG; DRUG EFFECT; ENDOVASCULAR SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMORAL ARTERY; GENE THERAPY; IN VIVO STUDY; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ADENOVIRUS; ANEURYSM; ANGIOGRAPHY; ANIMAL; CAROTID ARTERY; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PATHOLOGY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION;

ADENOVIRIDAE; ANEURYSM; ANGIOGRAPHY; ANIMALS; BLOTTING, WESTERN; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH, VASCULAR; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0141612795     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(03)00333-1     Document Type: Article

References (30)

1. Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002;360:1267-74.
2. Koivisto T, Vanninen R, Hurskainen H, Saari T, Hernesniemi J, Vapalahti M. outcomes of early endovascular versus surgical treatment of ruptured cerebral aneurysms: a prospective randomized study. Stroke 2000;31:2369-77.
3. Raymond J, Leblanc P, Desfaits AC, Salazkin I, Morel F, Janicki C, et al. In situ beta radiation to prevent recanalization after coil embolization of cerebral aneurysms. Stroke 2002;33:421-7.
4. Dattilo JB, Brewster DC, Fan CM, Geller SC, Cambria RP, Lamuraglia GM, et al. Clinical failures of endovascular abdominal aortic aneurysm repair: incidence, causes, and management. J Vasc Surg 2002;35:1137-44.
5. Bernhard VM, Mitchell RS, Matsumura JS, Brewster DC, Decker M, Lamparello P, et al. Ruptured abdominal aortic aneurysm after endovascular repair. J Vasc Surg 2002;35:1155-62.
6. Parry DJ, Kessel DO, Robertson I, Denton L, Patel JV, Berridge DC, et al. Type II endoleaks: predictable, preventable, and sometimes treatable? J Vasc Surg 2002;36:105-10.
7. Veith FJ, Baum RA, Ohki T, Amor M, Adiseshiah M, Blankensteijn JD, et al. Nature and significance of endoleaks and endotension: summary of opinions expressed at an international conference. J Vasc Surg 2002;35:1029-35.
8. Schurink GW, Aarts NJ, van Bockel JH. Endoleak after stent-graft treatment of abdominal aortic aneurysm: a meta-analysis of clinical studies. Br J Surg 1999;86:581-7.
9. Gorich J, Rilinger N, Sokiranski R, Orend KH, Ermis C, Kramer SC, et al. Leakages after endovascular repair of aortic aneurysms: classification based on findings at CT, angiography, and radiography. Radiology 1999;213:767-72.
10. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, et al. Recombinant platelet-derived growth fictor β gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest 1993; 91:1822-9.
11. Desfaits AC, Raymond J, Muizelaar JP. Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization. Stroke 2000;31:498-507.
12. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
13. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991;113:981-6.
14. Raymond J, Sauvageau E, Salazkin T, Ribourtout E, Gevry G, Desfaits AC. Role of the endothelial lining in persistence of residual lesions and growth of recurrences after endovascular treatment of experimental aneurysms. Stroke 2002;33:850-5.
15. Raymond J, Desfaits AC, Roy D. Fibrinogen and vascular smooth muscle cell grafts promote healing of experimental aneurysms treated by embolization. Stroke 1999;30:1657-64.
16. Ross R. The smooth muscle cell. II: Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-86.
17. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-84.
18. Hadrava V, Tremblay J, Harriet P. Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 1989;13(6 Pt 1):589-97.
19. 3H-proline- labeled protein by rapid filtration in multiwell plates for the study of collagen metabolism. Biotechniques 1997;22:706-8, 710-2, 714.
20. Raymond J, Venne D, Allas S, Roy D, Oliva VL, Denbow N, et al. Healing mechanisms in experimental aneurysms. T: Vascular smooth muscle cells and neointima formation. J Neuroradiol 1999;26:7-20.
21. Graves VB, Strother CM, Rappe AH. Treatment of experimental canine carotid aneurysms with platinum coils. AJNR 1993;14:787-93.
22. Kallmes DF, Williams AD, Cloft HJ, Lopes MB, Hankins GR, Helm GA. Platinum coil-mediated implantation of growth factor-secreting endovascular tissue grafts: an in vivo study. Radiology 1998;207:519-23.
23. Schwartz SM, Reidy MA, O'Brien ER. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995;74:541-51.
24. Noble NA, Harper JR, Border WA. In vivo interactions of TGF-beta and extracellular matrix. Prog Growth Factor Res 1992;4:369-82.
25. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-15.
26. 1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-76.
27. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, et al. TGF-beta latency: biological significance and mechanisms of activation. Stem Cells 1997;15:190-7.
28. Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000;352(Pt 3):601-10.
29. Wakefield LM, Smith DM, Broz S, Jackson M, Levinson AD, Sporn MB. Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors 1989;1:203-18.
30. Abrahams JM, Song C, DeFelice S, Grady MS, Diamond SL, Levy RJ. Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering. Stroke 2002;33:1376-82.